Inside Cognixion’s Non-Invasive BCI Study: Advancing Communication Through Thought

A new feature in Clinical Leader highlights Cognixion’s ongoing feasibility study of the Axon-R™ non-invasive brain-computer interface headset and the Nucleus™ bio-sensing hub. The study explores how combinations of brain signals, eye tracking, and AI can support communication for people with ALS and other conditions that affect speech.

In the interview, Cognixion CTO Chris Ullrich discusses how the Axon-R and Nucleus platform integrates with Apple Vision Pro, the role of patient and caregiver feedback in shaping the system, and the importance of responsible clinical and regulatory development. The focus is on creating a communication pathway that is intuitive, adaptable, and designed to meet real-world needs.

Read the full story on Clinical Leader:
Non-Invasive Brain-Computer Interface Trial Balances Regulatory Requirements With Patient Needs

Redefining Accessibility: How Apple Vision Pro and Cognixion Are Advancing Non-Invasive Brain-Computer Interfaces

Redefining Accessibility: How Apple Vision Pro and Cognixion Are Advancing Non-Invasive Brain-Computer Interfaces

November 2025

Cognixion was recently featured in 9to5Mac’s Apple @ Work, highlighting how Apple Vision Pro is helping advance accessibility through non-invasive brain-computer interfaces (BCIs). The feature explores how Cognixion’s ongoing clinical study is using Vision Pro to better understand how people living with ALS, spinal cord injuries, stroke, or traumatic brain injury can communicate using a combination of brain signals, eye tracking, and artificial intelligence.

Building on a Shared Vision for Accessibility

At Cognixion, we believe accessibility and innovation go hand in hand. By pairing Cognixion’s EEG-based Nucleus™ technology with Apple’s accessibility features such as Eye Tracking, Dwell Control, and Switch Control, the study is testing new ways for individuals with limited mobility or speech ability to interact with technology through thought and gaze alone.

“Apple has set a global standard by making accessibility integral to every device, and Apple Vision Pro extends that commitment to spatial computing,” said Andreas Forsland, CEO of Cognixion. “By exploring how Cognixion’s non-invasive BCI technology and AI applications can work with Apple’s accessibility features, we hope to unlock new levels of independence and connection for people living with neurological conditions. Our focus is on improving lives today without requiring surgery or tethered systems.”

The study will run through April 2026 and is part of Cognixion’s broader mission to develop non-invasive neuroadaptive systems that restore communication and empower individuals to live more independently. More than 14 million people in the United States live with neurological conditions that affect communication. This research represents a meaningful step toward expanding access and independence without the need for implanted devices.

Why Apple Vision Pro

Apple Vision Pro’s hardware and accessibility frameworks provide a strong foundation for innovation in healthcare. The device’s high-resolution video passthrough allows users to see and interact with the real world while digital overlays support new modes of communication. Apple’s long-standing investment in accessibility APIs and human-centered design makes Vision Pro an ideal platform for medical research that bridges physical and digital environments.

By integrating Cognixion’s BCI systems with Apple’s spatial computing environment, researchers are able to focus on decoding EEG signals and AI-driven communication models without reinventing the operating system or user interface. It is an example of how cross-industry collaboration can accelerate discovery and improve lives.

Looking Toward the Future

Cognixion’s work with Vision Pro highlights the power of inclusive design and the potential of non-invasive BCIs to redefine what accessibility means. This is not just a technological milestone; it is a human one.

As spatial computing evolves, it is becoming clear that the most transformative innovations are often the quiet ones that remove barriers, restore connection, and give people new ways to participate in the world around them.

At Cognixion, we are committed to that mission — building technologies that empower communication, connection, and independence for everyone.

🔗 Read the full article on 9to5Mac: How Apple Vision Pro is helping redefine accessibility through non-invasive brain-computer interfaces

#Accessibility #AI #BCI #Neurotech #AppleVisionPro #DigitalHealth #AssistiveTech #Innovation #Cognixion

Apple @ Work: Cognixion Episode featuring CTO Chris Ullrich

This episode of Apple @ Work features our very own CTO Chris Ullrich. Chris joins the show to talk about how the company is using Apple Vision Pro in a new clinical study to help people with conditions like ALS, spinal cord injuries, and stroke-related impairments communicate through a combination of brain signals, eye tracking, and AI.

To listen to the full podcast head over to Apple @ Work

MedTech World: Best Patient Impact of the Year Award

We have made it to the final nominee round 🏆 MedTech World Awards 2025 nominees announced! MedTech World recognized organizations transforming the MedTech landscape worldwide. 🌍

Cognixion has been nominated for…

Best Patient Impact of the Year 

Honoring initiatives that significantly improve patient outcomes and experiences

We would love your support 🗳️ Vote now: https://share-eu1.hsforms.com/13-RbKJs6SMKtx2-6rGPGKw2dl0pi

Cognixion is in the second set of nominees for Best Patient Impact of the Year

🏆 Winners will be announced during the MedTech Malta Gala Awards on 14th November!

📍 MedTech Malta 2025

🗓️ 12–14 November | Valletta, Malta

Cognixion named TIME Best Inventions of 2025

We’re thrilled to share some exciting news! TIME Magazine has named Cognixion to its list of Best Inventions of 2025, honoring breakthroughs that are transforming lives.

Our inclusion celebrates the incredible work of our team, research partners, Brainiacs, and Cognixion community who share one mission: to restore connection and communication through technology that is accessible, human, and empowering.

Unlike invasive brain implants that require surgery, the Cognixion Axon-R is a wearable, non-surgical brain–computer interface powered by adaptive, conversational AI. Giving people who have lost their ability to speak new ways to communicate and connect.

“Being included in TIME’s Best Inventions list is a profound moment for Cognixion — but it belongs to millions who cannot speak,” said Andreas Forsland, Founder & CEO of Cognixion. “Our goal is to make communication accessible again. With deeply personalized AI built into our system, nonverbal users can engage in fluent conversation. This marks a turning point for individuals who have long been locked inside their bodies. Our vision is clear: noninvasive, mobile, and accessible for everyone — widening the path for all to fully participate in life.”

We are honored to have the Axon-R recognized by TIME as one of the Best Inventions of 2025, marking a historic milestone for non-invasive brain-computer interfaces. The Axon-R combines EEG neurotechnology, on-device AI classification, and a spatial computing interface designed for assistive communication, a convergence that until now had existed only in research labs.

While TIME has previously honored invasive neurotechnology such as deep-brain stimulation systems, this recognition marks the first time a non-surgical, wearable interface has received such distinction. It underscores how AI and neurotechnology have moved from concept to reality, with Cognixion emerging as a leader in making these advances practical, human, and accessible.

👉Read more about our TIME Best Invention award

Clinical Trial News: Cognixion + Apple Vision Pro

🧠 Unlocking Communication: Cognixion Launches Clinical Study Integrating Noninvasive BCI with Apple Vision Pro

Cognixion is taking a bold step toward making brain–computer interface (BCI) technology more accessible than ever. We have launched a new clinical study integrating our noninvasive EEG-based BCI with the Apple Vision Pro, with the goal of enabling individuals with severe speech and mobility impairments to communicate and interact through thought, gaze, or head movement, without surgery.

Breaking Barriers with Accessible Neurotechnology

The study will evaluate how Cognixion’s Nucleus™ bio-sensing hub and advanced EEG montage can work alongside Apple Vision Pro’s powerful accessibility features. Including Eye Tracking and Dwell Control to create a new model of hands-free, voice-free communication.

Participants will include individuals affected by ALS (amyotrophic lateral sclerosis), spinal cord injury (SCI), stroke, and traumatic brain injury (TBI). Our study’s primary goal is to enable natural, conversational communication between participants and their caregivers, families, and communities — restoring independence through inclusive innovation.

Designed for Connection, Not Surgery

“Apple has set a global standard by making accessibility integral to every device, and Apple Vision Pro extends that commitment to spatial computing,” said Andreas Forsland, Founder and CEO of Cognixion.

“By exploring how Cognixion's non-invasive BCI technology and AI applications can work with Apple's accessibility features, we hope to unlock new levels of independence and connection for people living with ALS, spinal cord injuries, stroke, and traumatic brain injuries. Our focus is on improving lives today without requiring surgery or tethered systems.”

This integration will allow researchers to test new assistive pathways, leveraging combinations of brain signals, eye gaze, and head pose, that enable faster, more natural communication and computer interaction.

A Shared Vision for Accessibility

In the United States alone, over 14 million people live with chronic neurological conditions, and nearly 1 million more are diagnosed each year. Of these, more than 750,000 individuals experience limited access to reliable communication tools due to paralysis or speech impairment.

Our work at Cognixion aligns with Apple’s philosophy that accessibility is not an add-on — it’s a fundamental right. Together, this study underscores how neurotechnology and spatial computing can combine to expand independence and improve quality of life.

“This study is about understanding the patient experience — what happens when advanced accessibility features meet new neural input methods,” said Chris Ullrich, Cognixion’s Chief Technology Officer and principal investigator for the clinical trial. “We’re learning from each participant’s lived experience to design solutions that are meaningful and delightful.”

Building Toward the Future

Beyond communication, we plan to explore Assisted Reality use cases. From controlling mobility devices to accessing entertainment, education, and work, all through a seamless, noninvasive interface.

This study marks one of the first clinical explorations of a noninvasive EEG-based BCI integrated with Apple Vision Pro, setting the stage for a new era in inclusive technology. Following this feasibility study, Our clinical trial is currently underway. To learn more click here.

Get Involved

Individuals interested in participating in the study can reach out to clinicaltrials@cognixion.com with “Cognixion-spatial computing study” in the subject line.

A New Way to Communicate for People Living with ALS

A New Way to Communicate for People Living with ALS

As featured in The Goodnewspaper- The Tech Edition

For people with amyotrophic lateral sclerosis (ALS), the gradual loss of muscle control often leads to challenges with speaking and, eventually, even moving their eyes. Many assistive communication tools rely on eye movement, so when that ability is lost, options for staying connected become extremely limited.

Cognixion has developed a new approach that could help. The Axon-R headset combines brain-computer interface (BCI) technology with artificial intelligence (AI) and augmented reality (AR) to create a communication system that doesn’t depend on speech or motor control.

The headset works by using small sensors to detect brain responses to flashing visual patterns. Those responses are then interpreted by AI to select letters, words, or commands. This allows the user to communicate even without physical movement. The built-in AR display helps create an interactive, accessible experience for the person wearing it.

The goal of the Axon-R is simple: give people with advanced ALS another way to share their thoughts, needs, and ideas with those around them. While it’s still an emerging technology, it represents a step forward in making communication more inclusive for people with severe motor impairments.

To see the full feature, click here

Cognixion and Pupil Labs Announce Strategic Partnership to Combine Eye-Tracking with Axon-R Neural Interface

Integration of Eye-Tracking and AI-Powered EEG BCI Technologies Opens New Frontiers for Clinical Researchers

SANTA BARBARA, Calif. and BERLIN – JUNE 4, 2025 — We’re excited to announce our partnership with Pupil Labs GmbH. By combining Cognixion’s noninvasive Brain-Computer Interface (BCI), Artificial Intelligence (AI), and Augmented Reality (AR) technologies with Pupil Labs’ advanced eye-tracking solutions, we’re creating a powerful new interface that measures both visual attention and neural signals. Their eye-tracking software will integrate with the Axon-R SDK, enabling seamless, cross-platform data collection and analysis.

High-precision eye tracking and advanced BCI electroencephalogram (EEG) capabilities will give clinical researchers powerful new tools for neuroscience, human-computer interaction, and assistive technology research. The combined technology will provide a higher level of data confidence, and a platform that can adapt to the unique needs of patients where disease progression may impact eye gaze ability, such as amyotrophic lateral sclerosis (ALS). The partnership addresses a significant need in the research community for unified tools that can simultaneously track visual attention and neural activity with research-grade precision.

"By combining Cognixion's neural interface expertise with Pupil Labs' industry-leading eye tracking technology, we're filling a critical role in sensor architecture that isn’t available with any current brain-computer interface technologies," said Andreas Forsland, CEO of Cognixion.

"This partnership enables a new generation of studies that can correlate visual attention with neural activity in real-time, potentially transforming our understanding of human cognition and interaction."

The integrated solution will allow researchers to:

● Rapidly prototype and deploy studies that simultaneously measure eye movements and brain activity

● Leverage research-grade sensors for both modalities without complex technical integration

● Access synchronized data streams through a unified developer interface

● Develop applications that respond to both visual attention and neural signals

"We've seen growing demand for combined eye-tracking and EEG solutions from our research partners," said Moritz Kassner, CEO of Pupil Labs. "This collaboration with Cognixion addresses that need with a seamless integration that maintains the fidelity researchers expect from both technologies while dramatically reducing technical barriers."

The integration is expected to be particularly valuable for clinical researchers studying attention, cognitive load, human-computer interaction, and assistive technologies for individuals with motor impairments.

Technical teams from both companies have begun the integration process, with initial releases expected within six months. The companies will also collaborate on joint marketing efforts and educational resources for the research community.

About Cognixion

Cognixion is a leader in brain-computer, augmented reality, artificial intelligence and natural user interface technology. The company is dedicated to improving the lives of individuals with severe motor impairments by providing cutting-edge patented technology that allows them to independently communicate and restore physical interactions with the world around them. The Cognixion ONE™ device is the company's flagship product, and it has already received significant recognition for its design and potential to transform the lives of individuals with severe motor impairments. Cognixion has received FDA Breakthrough Device Designation for its derivative version called Cognixion ONE Axon. The work described in this study is built upon the Cognixion ONE Axon-R, which is a version of the Axon made specifically for research purposes and is not currently cleared by the FDA as a medical device.

About Pupil Labs

Pupil Labs is a Berlin-based company that has been pioneering wearable eye-tracking technology since 2014. At the core of their platform is NeonNet, a state-of-the-art deep learning pipeline that delivers robust, calibration-free performance. NeonNet delivers rich data — gaze, pupil diameter, blinks, and more — with research-grade precision and reliability, setting a new benchmark for real-world eye tracking. Today, Pupil Labs supports a global community of over 10,000 professional users, with nearly 1,000 scientific publications produced using their tools.

http://pupil-labs.com/

For more information, please contact:

Ben Williamson – VP, Strategic Partnerships Cognixion Corporation (Connect with them here)

Marc Pieper- Product Lead & Partner, Pupil Labs GmbH (Connect with them here)

Cognixion Featured on CBS News

We’re excited to share that Cognixion was recently featured on CBS News & the Y-Axis, the tech and innovation newsletter by Yasmin Khorram.

In her latest post, “The Great Brain-Computer Race Heats Up,” Khorram dives into the fast-growing world of brain-computer interfaces (BCIs), where startups, tech giants, and researchers are racing to build the next generation of human-machine interaction tools.

We’re proud that Cognixion’s unique approach to BCI technology is included in this discussion — especially as a company focused on making this future accessible, non-invasive, and real-world ready today.

Our Vision: BCI Without Surgery

Unlike many players in the BCI space focused on implantable devices, Cognixion is building a wearable, AI-powered neural interface that combines:

• Non-invasive EEG

• Augmented reality

• Eye tracking and visual feedback

• Assistive communication tools

Our platform, Axon-R, is already in use by researchers and is currently being studied in an ongoing clinical trial with individuals living with ALS. The goal? To restore communication and connection, without the need for surgery.

A More Inclusive Neurotech Future

Khorram’s article explores the growing interest in BCI from companies like Neuralink and Precision Neuroscience, but it also shines a light on why accessibility matters in the rush to innovate.

“While many startups are pursuing surgically implanted devices, Cognixion is developing a non-invasive, wearable headset designed for people with speech and motor disabilities.”
— Yasmin Khorram, Play On

At Cognixion, we believe that the future of BCI should be inclusive, ethical, and designed with the end-user in mind, not only for labs but for everyday life.

📖 Read the full feature here:
The Great Brain-Computer Race Heats Up – Play On by Yasmin Khorram

🔬 Want to learn more about our clinical trial or research platform?
Explore Cognixion Axon-R

Cognixion and Blackrock Neurotech Expand Access to Non-Invasive, Multi-Modal BCI Research with Axon-R

Cognixion and Blackrock Neurotech Expand Access to Non-Invasive, Multi-Modal BCI Research with Axon-R

Blackrock Neurotech to begin immediate sales of Cognixion’s Axon-R wearable BCI + augmented reality platform, paving the way for integration of implantable BCI with immersive computing applications

Santa Barbara, CA — [5/14/25] — Cognixion, a leading developer of non-invasive brain-computer interface (BCI), artificial intelligence (AI) and augmented reality (AR) technology, today announced that Blackrock Neurotech, a leading developer of implantable BCIs, will offer Cognixion’s Axon-R wearable neural interface platform to research institutions through its distribution network.

Cognixion and Blackrock Neurotech maintain independent development activities but share a common vision: advancing the field of neurotechnology through expanded access to cutting-edge research tools. Under this offering, Blackrock Neurotech will act as a non-exclusive distributor of Cognixion’s Axon-R device, which is a non-invasive, wearable device that enables precise measurement and modulation of brain activity through visual stimuli, biofeedback, and neurofeedback, and is intended solely for investigational and educational use.

"This collaboration represents a powerful alignment of complementary technologies that will have an outsized impact across neurotechnology applications," said Andreas Forsland, CEO of Cognixion. "Blackrock Neurotech's implant technology combined with Cognixion's AI and augmented reality platform will open new doors for researchers and clinicians alike, while providing transformative solutions to the individuals we ultimately serve."

“At Blackrock Neurotech, our mission is restoring capability,” said Marcus Gerhardt, CEO of Blackrock Neurotech. “By expanding access to research-grade tools like Axon-R, we aim to support the early exploration of neural interfaces while maintaining our clinical focus on sovereign, high-fidelity implantable technologies that restore speech, movement, and sensation.”

The Axon-R system provides non-invasive brain monitoring capabilities that are ideal for foundational training and investigational research initiatives. While Blackrock Neurotech’s core focus remains on implantable, sovereign BCIs that restore speech, movement, and sensation, the availability of research-grade tools like the Axon-R opens new pathways for multidisciplinary innovation.

The immediate availability of Axon-R alongside clinical implantable solutions enables universities, hospitals, and academic programs to engage more deeply in BCI research, education, and investigational studies. By pairing Blackrock Neurotech’s implant technology with Cognixion’s Axon-R platform, researchers and hospitals can collect high-quality data from surface-level EEG alongside implanted BCI data in a time-synchronized manner. Early exposure to multi-modal, state-of-the-art BCI tools can empower clinical leaders to push the frontiers of medical science and patient care.

The Axon-R device is a research-grade, non-invasive BCI designed to support investigational use in neuroscience, neurorehabilitation, and education. The Axon-R is intended solely for research applications and is not cleared by the U.S. Food and Drug Administration (FDA) for clinical or therapeutic applications. Blackrock Neurotech acts solely as a distributor of the Axon-R for research use and does not develop, modify, or clinically endorse the device. Any future investigations involving multi-modal research across non-invasive and implantable systems are exploratory in nature and remain subject to independent validation.

About Cognixion:

Cognixion is a leader in brain-computer, augmented reality, artificial intelligence and neural user interface technology. The company is dedicated to improving the lives of individuals with severe motor impairments by providing cutting-edge patented technology that allows them to independently communicate and restore physical interactions with the world around them. The Cognixion ONE™ device is the company's flagship product, and it has already received significant recognition for its design and potential to transform the lives of individuals with severe motor impairments. Cognixion has received FDA Breakthrough Device Designation for its derivative version called, Cognixion ONE Axon. The work described in this study is built upon the Cognixion ONE Axon-R, which is a version of the Axon made specifically for research purposes and is not currently cleared by the FDA as a medical device.

About Blackrock Neurotech:

Blackrock Neurotech is a leading developer of implantable brain-computer interfaces (BCIs), empowering individuals and researchers to explore new frontiers in neuroscience and clinical care. Blackrock's technology has been at the forefront of breakthrough discoveries in human cognition and motor function restoration for over 15 years. 

For more information, please contact:

Ben Williamson – VP, Strategic Partnerships Cognixion Corporation (Connect with them here)

Gregory Palis – Director of Sales, Blackrock Neurotech (Connect with them here)

https://blackrockneurotech.com/

https://www.cognixion.com/

ALS News Today Spotlights Cognixion’s Clinical Trial for Non-Invasive BCI Headset

ALS News Today Spotlights Cognixion’s Clinical Trial for Non-Invasive BCI Headset

ALS News Today recently featured Cognixion in an article titled “Cognixion Seeks ALS Patients for Clinical Trial of BCI Headset”. The piece highlights our efforts to recruit participants living with ALS for a clinical study of our non-invasive brain-computer interface (BCI) headset, Cognixion ONE Axon.

This study represents a major step forward in our mission to deliver accessible communication technology to people with severe motor and speech impairments — and to validate it in partnership with the ALS community.

What the Study Involves

Our FDA Breakthrough Device–designated Cognixion ONE is a wearable headset that uses EEG brain signals, eye-tracking, augmented reality, and AI-assisted communication tools to enable users to speak and interact — even when traditional access methods are no longer possible.

This upcoming clinical trial will evaluate:

• The headset’s usability and comfort

• Its effectiveness in supporting communication

• The experience of individuals with ALS and related motor disabilities

“We’re focused on building technology that empowers people with ALS to express themselves independently — no surgery required.”
— Andreas Forsland, CEO & Founder of Cognixion

Why It Matters.

As ALS News Today reports, people with ALS often experience a progressive loss of motor and speech function. Existing communication devices may become too difficult to use over time, leaving individuals isolated.

Our headset was designed specifically to address that challenge — offering a hands-free, voice-free, surgery-free path to communication, built with direct feedback from individuals affected by ALS and their caregivers.

By participating in this study, individuals can help shape the next generation of non-invasive assistive technology — technology that could soon be available for real-world use in clinics, care facilities, and homes.

How to Get Involved

If you or someone you know is living with ALS and interested in participating, we encourage you to learn more:

🔗 Read the full article:
ALS News Today – Cognixion Seeks ALS Patients for Clinical Trial

📩 Learn more about the study or express interest:
https://clinicaltrials.gov/study/NCT06810219

IEEE Spectrum Highlights New Frontiers in ALS Communication

IEEE Spectrum Highlights New Frontiers in ALS Communication — and Cognixion is Proud to Be Part of the Movement

A recent article from IEEE Spectrum titled “How BCIs Are Helping People With ALS Communicate Again” offers a powerful look at the growing impact of brain-computer interface (BCI) technology on people living with ALS. We’re honored that Cognixion’s work is part of this important conversation.

ALS (amyotrophic lateral sclerosis) is a progressive neurodegenerative disease that affects motor function, often leading to complete loss of speech and mobility. But thanks to advancements in neurotechnology — including both implantable and non-invasive BCIs — new doors are opening for individuals who once faced complete communication isolation.

Our Approach: Non-Invasive, Accessible, and Designed for Daily Life

At Cognixion, we’ve taken a different path from many BCI innovators. While some focus on surgically implanted systems, we’ve pioneered a wearable neural interface that combines non-invasive EEG, augmented reality (AR), and AI-powered assistive communication — no surgery required.

Our Cognixion ONE Axon system is designed specifically for individuals with severe speech and motor impairments, offering:

• 💬 Real-time communication via brain signals

• 🧠 Non-invasive EEG-based control

• 🕶️ An integrated AR display with eye-tracking and biofeedback

• 🌐 Tools for speaking, typing, and interacting with digital environments

Importantly, it's designed to be used at home, in clinics, and in everyday settings — putting powerful BCI tools into the hands of people who need them most, without the clinical barriers or surgical risks.

Why This Matters for ALS

As IEEE Spectrum notes, restoring communication for people with ALS is not just a technological challenge — it's a human rights issue. Every person deserves the ability to express themselves, connect with others, and maintain autonomy as their condition progresses.

That’s why we’ve built Cognixion ONE Axon and our research platform, Axon-R, with accessibility at the core. Our devices are developed in collaboration with people living with ALS and other neurodegenerative diseases, as well as their families, caregivers, and clinicians.

“The more we lower the barriers to communication, the more dignity, independence, and humanity we can help preserve.”
— Andreas Forsland, CEO & Founder of Cognixion

Moving Forward Together

We applaud the work of fellow innovators in the BCI space — including those featured in the IEEE article — who are pushing the limits of what's possible for people with ALS. Whether it’s through implants, wearables, or hybrid systems, our shared mission is to restore connection.

At Cognixion, we’re committed to developing solutions that are not just powerful, but practical, affordable, and ready for real-world use.

📖 Read the full IEEE Spectrum article here:
👉 How BCIs Are Helping People With ALS Communicate Again

🔍 Learn more about our open clinical trial:
👉 Click Here

Cognixion Featured in Forbes: Expanding Access to BCI Without Surgery

Check out our feature in Forbes for our work advancing non-invasive brain-computer interface (BCI) technology that empowers individuals with disabilities, without the need for surgery.

In the article, “This Startup Lets Paralyzed People Use Computers—Without a Chip in Their Head,” Forbes contributor Alex Knapp highlights how Cognixion’s Axon-R platform is changing the game for people with severe motor impairments by providing a wearable, AI-powered neural interface that works right out of the box.

🧠 No implants.
🕶️ No operating room.
💬 Just real-time communication and control through thought.

Making BCI More Accessible

At Cognixion, we believe brain-computer interface technology should be inclusive, affordable, and accessible.

Our Axon-R system combines:

• Non-invasive EEG sensors that read brain signals from the scalp

• Artificial intelligence to interpret intent and attention

• Augmented reality to provide a visual, interactive environment

• Assistive communication tools for real-time expression and interaction

As Forbes notes, what sets Cognixion apart is our focus on usability and accessibility, developed with and for people who live with ALS, cerebral palsy, spinal cord injuries, and other conditions that affect mobility and speech.

From Lab to Life

Many of the world’s leading BCI companies are developing powerful implantable systems — and we celebrate those advancements. But at Cognixion, our mission is to bring BCI technology out of the lab and into everyday life. That means designing devices that can be worn comfortably, used independently, and integrated into real-world environments like homes, schools, and care facilities.

Our flagship system, Cognixion ONE Axon, received FDA Breakthrough Device Designation and is undergoing further development for clinical applications. In parallel, our Axon-R platform is available today for research and investigational use — helping universities and healthcare institutions explore the future of multimodal neurotechnology.

Thank You, Forbes

We’re grateful to Forbes for spotlighting the progress being made in non-invasive BCI and for recognizing the importance of accessible innovation. The people we serve are not waiting for the future — they are building it with us.

📖 Read the full article here:
👉 This Startup Lets Paralyzed People Use Computers—Without a Chip in Their Head

Want to learn more or collaborate with us?
Visit www.cognixion.com to explore our research platform and assistive technologies.

Cognixion MedTech World Startup of the Year

🎥 Excited to share this video interview with our CEO Andreas Forsland at MedTech World Malta 2024! 🌍✨

During our time at the event, we explored how emerging technologies like #BCI, #AR, and #AI are transforming #Neurology and driving innovation in #SaMD and #HealthSystems. It was an incredible opportunity to connect with visionaries and showcase how platforms like ours are pushing the boundaries of what’s possible in healthcare.

A heartfelt thank you to Giovanni Lauricella, Yulia Yurevich, Dylan Attard MD, MRCSI, MEnt., and the entire team at MedTech World for coordinating such a phenomenal event and for making our visit unforgettable.

We are deeply honored to be recognized as the 2024 MedTech Startup of the Year, a milestone that underscores the dedication and passion of our entire team. 🙌💡

🚀 Watch the full interview here

To learn more about our work with the Cognixion ONE Axon-R hear to https://axon-r.cognixion.com/

#Neurology #SaMD #Platform #HealthSystems #BCI #AR #AI

AI for Good Summit: Cognixion One on One

New Video Alert! 🎥

Roll the clip from the AI for Good Global Summit, where our CEO @Andreas Forsland shares his exclusive perspectives! 🚀 Dive into his insight and discover key takeaways on advancing global development priorities through AI.

Check it out here:

We were honored to attend the AI for Good Global Summit which is the leading action-oriented United Nations platform promoting AI to advance health, climate, gender, inclusive prosperity, sustainable infrastructure, and other global development priorities. AI for Good is organized by the International Telecommunication Union (ITU) – the UN specialized agency for information and communication technology – in partnership with 40 UN sister agencies and co-convened with the government of Switzerland.

Don't forget to like, comment, and share your thoughts! Let's learn and grow together. 💡✨

#AssistiveTechnolofy #Learning #Growth #AIforGood #Innovation #GlobalDevelopment #Cognixion #AI #Technology

Cognixion: Pioneering a New Path in Brain-Computer Interface Adoption

Cognixion: Pioneering a New Path in Brain-Computer Interface Adoption

In the rapidly evolving field of brain-computer interfaces (BCIs), Cognixion is emerging as a formidable player, offering a distinct approach compared to its well-known rival, Neuralink. Backed by Amazon, Cognixion is dedicated to transforming the lives of individuals with disabilities through non-invasive BCI technology. Andreas Forsland, the founder and CEO of Cognixion, sheds light on the company's unique strategy and vision.

A Different Approach to BCI

While Neuralink, founded by Elon Musk, focuses on high-definition, implantable chips that require surgical procedures, Cognixion is taking a different route. Forsland emphasizes that Cognixion's non-invasive BCI headsets are designed to be accessible and practical for a broader audience. “Neuralink is an interesting technology, but it requires surgery, and most people are not going to volunteer for that,” Forsland told Observer. He added that only extreme use cases with high-needs neurological conditions would necessitate such invasive procedures, and most neurologists would avoid prescribing implants unless absolutely necessary.

Patient Advocacy Over Technology Investment

Cognixion's journey in the BCI space began in 2015, around the same time as Neuralink. However, Forsland points out a fundamental difference in their focus. “They focus much more on technology investment. We focus much more on patient advocacy,” he said. Cognixion aims to provide solutions that are less risky and more immediately beneficial to users. Their non-invasive headsets can unlock a variety of use cases, particularly in healthcare, by enabling speech through a speaker and a mirrored screen, accessing apps for home automation and entertainment, and tracking physiological data.

Strategic Partnerships and Clinical Collaborations

Cognixion's innovative approach has attracted significant investment from Amazon, which includes integrating Amazon Alexa technology into Cognixion devices. This integration allows patients to have full smart home controls, enhancing their independence and quality of life. Forsland also hinted at future partnerships with other major companies, further solidifying Cognixion's position in the market. On the clinical side, Cognixion's Axon-R is collaborating with prestigious institutions such as Johns Hopkins, Mass General, Northwell Health, Memorial Hermann Health System, and the Veterans Health Administration.

Scaling Impact and Regulatory Milestones

Forsland envisions a future where Cognixion's technology can scale to millions of people within years, not decades. The company has already received the FDA Breakthrough Device designation, which fast-tracks its approval process. Despite the regulatory challenges, Cognixion's products are already in clinical and laboratory use, and the company aims to become the first fully FDA-cleared BCI device.

Empowering Independence

The potential impact of Cognixion's technology extends beyond the individuals using it to their caregivers and families. Forsland explains, “Our system can enable individuals to be more independent of communication, smart home controls, mobility controls, where it reframes the role of the caregiver to a true companion versus somebody who just needs to suction a tracheostomy or turn on off the lights or change TV channels.” This ripple effect of increased independence and empowerment is at the heart of Cognixion's mission.

Conclusion

Cognixion is charting a new course in the BCI landscape, prioritizing patient advocacy and non-invasive solutions over high-risk, invasive procedures. With strategic partnerships, clinical collaborations, and a clear vision for the future, Cognixion is poised to make a significant impact on the lives of millions of people with disabilities. As Forsland aptly puts it, “If you think about a future where people are using their brain, especially people with disabilities, our technology can scale to millions of people within years, not decades”

Read the full article featured on Observer here

Mindblowing Neurotechnology, Cognixion CEO at Aspen Ideas Festival

Mindblowing Neurotechnology… 

featuring never before seen Cognixion ONE demos of our wearable BCI +AR system

Our CEO Andreas Forsland spoke about the work we are doing at Cognixion in AI-powered BCI with AR.  Specifically for enabling speech generation to those who are minimally or non-verbal due to an acquired or degenerative condition specifically the complete #ALS journey.

He spoke alongside: 

Thomas Oxley, MD - Neurologist Synchron- Creators of a implantable vascular brain sensor resembling a stent) 

Kate Rosenbluth, PhD, Associate Professor at Stanford, CEO Cala Health- Creators of a wearable wristband with electrical stimulation for essential tremors

Nita Farahany, Esq-Legal scholar, Ethicist at Duke University, Author of The Battle for Your Brain

Make sure to watch the whole special below to see never before seen demos of our wearable BCI+Augmented Reality system by ALS patients in various stages from early (cervical control), mid (visual/eye control), and late stage/locked-in stage (mental attention control) using it to communicate.

To learn more about Cognixion ONE or to sign up to be first in line for updates head over to https://one.cognixion.com/ and sign up at the bottom to join our Cognixion community!